Therapeutic targeting of the CXCL10 and MAPK/ERK signaling pathways has gained ‎‎attention in cancer therapy as they play a central role in cancer progression, immune ‎modulation ‎and regulation of the tumor microenvironment. The gene discussed is CXCL10; the disease is cancer.